Discontinued — last reported Q4 '25
Pifeltro — Sales
Merck & Co. Pifeltro — Sales decreased by 3.5% to $83.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 5.1%, from $79.00M to $83.00M. Over 3 years (FY 2022 to FY 2025), Pifeltro — Sales shows an upward trend with a 13.2% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase in sales indicates successful market penetration, strong physician adoption, or effective competitive positioning, while a decrease may signal market saturation, the entry of generic alternatives, or shifts in clinical treatment guidelines.
Detailed definition
This metric represents the total gross revenue generated from the sale of a specific pharmaceutical product line within...
Peer comparison
Comparable to product-specific revenue reporting for branded therapeutics in the HIV or infectious disease segments of other large-cap pharmaceutical companies.
mrk_segment_pifeltro_salesHistorical Data
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $58.75M | $58.75M | $58.75M | $58.75M | $68.00M | $76.00M | $74.00M | $66.00M | $84.00M | $78.00M | $85.00M | $79.00M | $90.00M | $82.00M | $86.00M | $83.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +15.7% | +11.8% | -2.6% | -10.8% | +27.3% | -7.1% | +9.0% | -7.1% | +13.9% | -8.9% | +4.9% | -3.5% |
| YoY Change | — | — | — | — | +15.7% | +29.4% | +26.0% | +12.3% | +23.5% | +2.6% | +14.9% | +19.7% | +7.1% | +5.1% | +1.2% | +5.1% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Merck & Co.'s pifeltro — sales?
- Merck & Co. (MRK) reported pifeltro — sales of $83.00M in Q4 2025.
- How has Merck & Co.'s pifeltro — sales changed year-over-year?
- Merck & Co.'s pifeltro — sales increased by 5.1% year-over-year, from $79.00M to $83.00M.
- What is the long-term trend for Merck & Co.'s pifeltro — sales?
- Over 3 years (2022 to 2025), Merck & Co.'s pifeltro — sales has grown at a 13.2% compound annual growth rate (CAGR), from $235.00M to $341.00M.
- What does pifeltro — sales mean?
- The total annual revenue generated from the sales of the Pifeltro pharmaceutical product.